ECSP21072840A - Compuestos de neuregulina-4 y métodos de uso - Google Patents

Compuestos de neuregulina-4 y métodos de uso

Info

Publication number
ECSP21072840A
ECSP21072840A ECSENADI202172840A ECDI202172840A ECSP21072840A EC SP21072840 A ECSP21072840 A EC SP21072840A EC SENADI202172840 A ECSENADI202172840 A EC SENADI202172840A EC DI202172840 A ECDI202172840 A EC DI202172840A EC SP21072840 A ECSP21072840 A EC SP21072840A
Authority
EC
Ecuador
Prior art keywords
compounds
neuregulin
methods
nrg4
nrg
Prior art date
Application number
ECSENADI202172840A
Other languages
English (en)
Inventor
Josef George Heuer
Jonathan Wesley Day
James David Pancook
Wei Ni
Avinash Muppidi
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP21072840A publication Critical patent/ECSP21072840A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142—Pressure infusion, e.g. using pumps
    • A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
    • A61M5/14248—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body of the skin patch type
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a compuestos de neuregulina (NRG) 4 y métodos de tratamiento con compuestos de NRG4.
ECSENADI202172840A 2019-04-01 2021-09-30 Compuestos de neuregulina-4 y métodos de uso ECSP21072840A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962827386P 2019-04-01 2019-04-01

Publications (1)

Publication Number Publication Date
ECSP21072840A true ECSP21072840A (es) 2021-11-18

Family

ID=70465394

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202172840A ECSP21072840A (es) 2019-04-01 2021-09-30 Compuestos de neuregulina-4 y métodos de uso

Country Status (25)

Country Link
US (3) US11242370B2 (es)
EP (1) EP3947428A1 (es)
JP (1) JP7036953B2 (es)
KR (1) KR102717638B1 (es)
CN (1) CN113677699B (es)
AR (1) AR121035A1 (es)
AU (1) AU2020252184B2 (es)
BR (1) BR112021017670A2 (es)
CA (2) CA3132135A1 (es)
CL (1) CL2021002455A1 (es)
CO (1) CO2021012807A2 (es)
CR (1) CR20210474A (es)
DO (1) DOP2021000194A (es)
EA (1) EA202192288A1 (es)
EC (1) ECSP21072840A (es)
IL (1) IL286697A (es)
JO (1) JOP20210264A1 (es)
MA (1) MA55532A (es)
MX (1) MX2021011983A (es)
PE (1) PE20212326A1 (es)
PH (1) PH12021552427A1 (es)
SG (1) SG11202110484VA (es)
TW (1) TWI787596B (es)
WO (1) WO2020205840A1 (es)
ZA (2) ZA202106570B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3355909B1 (en) 2015-09-28 2023-06-07 Children's Hospital Los Angeles Methods for treating diseases mediated by erbb4-positive pro-inflammatory macrophages
AR121035A1 (es) * 2019-04-01 2022-04-13 Lilly Co Eli Compuestos de neuregulina-4 y métodos de uso
WO2023150693A2 (en) * 2022-02-03 2023-08-10 Avexegen Therapeutics, Inc. Neuregulin-4 analogs and methods of using thereof in disease treatment
EP4531892A1 (en) 2022-05-25 2025-04-09 Eli Lilly and Company Methods of using neuregulin-4 compounds
EP4572788A2 (en) * 2022-08-15 2025-06-25 The Regents of The University of Michigan Methods and compositions for treating cancer
WO2024163874A2 (en) * 2023-02-03 2024-08-08 Avexegen Therapeutics, Inc. Stable and controlled release formulations of neuregulin-4 analogs

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530109A (en) 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
US7115554B1 (en) 1993-05-06 2006-10-03 Acorda Therapeutics, Inc. Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III
US7037888B1 (en) 1992-04-03 2006-05-02 Acorda Therapeutics, Inc. Methods for treating muscle diseases and disorders
EP1028735A4 (en) 1997-10-14 2003-08-06 Cenes Pharmaceuticals Inc THERAPEUTIC METHOD COMPRISING THE USE OF NEUREGULIN
AUPP785098A0 (en) 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
US6635249B1 (en) 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
WO2001014415A2 (en) 1999-08-20 2001-03-01 Chiron Corporation Egfh2 genes and gene products
US6825333B1 (en) 1999-08-20 2004-11-30 Chiron Corporation EGFH2 genes and gene products
US7094882B2 (en) * 2000-04-21 2006-08-22 Yeda Research And Development Co. Ltd. Growth factor which acts through erb b-4 rtk
US6544759B1 (en) * 2000-04-21 2003-04-08 Yeda Research And Development Co. Ltd Polynucleotides encoding a novel growth factor which acts through ErbB-4 kinase receptor tyrosine
ES2610353T3 (es) 2000-05-23 2017-04-27 Cenes Pharmaceuticals, Inc. Moléculas de ácido nucleico NRG-2, polipéptidos y métodos diagnósticos y terapéuticos
US20040248196A1 (en) 2001-08-03 2004-12-09 Adams Timothy Edward Methods of screening based on the egf receptor crystal structure
WO2003025142A2 (en) 2001-09-16 2003-03-27 Nuvelo, Inc. Novel nucleic acids and secreted polypeptides
CN1498656A (zh) * 2002-11-08 2004-05-26 上海泽生科技开发有限公司 神经调节蛋白用于心肌梗死治疗的方法和组合物
AU2002304965A1 (en) * 2002-05-24 2003-12-12 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
AU2004265512B2 (en) 2003-08-19 2010-12-16 Yeda Research And Development Co Ltd Splice variants of ErbB ligands, compositions and uses thereof
US20070213264A1 (en) 2005-12-02 2007-09-13 Mingdong Zhou Neuregulin variants and methods of screening and using thereof
JP5738516B2 (ja) 2005-12-30 2015-06-24 ゼンサン （シャンハイ） サイエンス アンド テクノロジー リミテッド 心機能改善のためのニューレグリンの徐放
CN101394861A (zh) * 2005-12-30 2009-03-25 上海泽生科技开发有限公司 纽兰格林持续给药能改善心脏功能
NZ574093A (en) * 2006-06-12 2011-03-31 Symphogen As Pan-cell surface receptor- specific therapeutics
ES2315110B1 (es) 2006-07-14 2009-12-30 Universidad De Barcelona Compuestos para el tratamiento de enfermedades relacionadas con la resistencia a la insulina.
CN101310779A (zh) * 2007-05-25 2008-11-26 上海泽生科技开发有限公司 包含神经调节蛋白的装置及药物制剂
CN103432681A (zh) * 2007-05-25 2013-12-11 上海泽生科技开发有限公司 包含神经调节蛋白的药物制剂及装置
US20090156488A1 (en) 2007-09-12 2009-06-18 Zensun (Shanghai) Science & Technology Limited Use of neuregulin for organ preservation
CN101397337A (zh) * 2007-09-25 2009-04-01 上海泽生科技开发有限公司 神经调节蛋白突变体及其用途
US20110166068A1 (en) 2008-07-17 2011-07-07 Acorda Therapeutics, Inc. Therapeutic Dosing of a Neuregulin or a Subsequence Thereof for Treatment or Pro-phylaxis of Heart Failure
EP2328606B1 (en) 2008-08-15 2016-10-05 Acorda Therapeutics, Inc. Compositions and methods for treatment during non-acute periods following cns neurological injury
WO2010060266A1 (en) 2008-11-28 2010-06-03 Zensun (Shanghai) Science & Technology Limited Neuregulin and cardiac stem cells
EP2808339B1 (en) 2008-11-28 2017-02-15 Zensun (Shanghai) Science & Technology, Co., Ltd. Neuregulin peptides and their use
CN102470161A (zh) 2009-06-09 2012-05-23 上海泽生科技开发有限公司 神经调节蛋白用于治疗心力衰竭的有效剂量
WO2010142141A1 (en) 2009-06-09 2010-12-16 Zensun (Shanghai) Science & Technology Limited Neuregulin based methods for treating heart failure
WO2011006072A2 (en) 2009-07-10 2011-01-13 Northwestern University Cardioprotective role of hepatic cells and hepatocyte secretory factors in myocardial ischemia
WO2011011388A2 (en) 2009-07-22 2011-01-27 Children's Medical Center Corporation Neuregulin induced regeneraton of heart muscle muscle
JP6096262B2 (ja) 2009-08-25 2017-03-15 ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー． ニューレグリンに基づく心不全の治療方法
CN102139095A (zh) 2010-01-29 2011-08-03 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟心脏缺血再灌注损伤的方法和组合物
US9029328B2 (en) 2010-03-24 2015-05-12 The Brigham And Women's Hospital, Inc. Methods for cardioprotection and cardioregeneration with dimers of EGF family ligands
WO2013025817A1 (en) 2011-08-15 2013-02-21 Children's Hospital Los Angeles Use of neuregulin-4 for treatment of inflammatory bowel disease and necrotizing enterocolitis
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
WO2014051567A1 (en) 2012-09-26 2014-04-03 Morehouse School Of Medicine Chimeric neuregulins and method of making and use thereof
US8748131B2 (en) 2012-09-26 2014-06-10 Morehouse School Of Medicine Chimeric neuregulins and method of making and use thereof
BR112015006656A8 (pt) 2012-10-08 2020-01-21 Sensun Shanghai Science & Tech Co Ltd composições e métodos para o tratamento de insuficiência cardíaca em pacientes diabéticos
US20160129084A1 (en) 2013-03-06 2016-05-12 Acorda Therapeutics, Inc. Therapeutic Dosing of a Neuregulin or a Fragment Thereof for Treatment or Prophylaxis of Heart Failure
WO2014153385A2 (en) 2013-03-21 2014-09-25 The Regents Of The University Of Michigan Methods of treating metabolic disorders
EP2999499B1 (en) * 2013-05-22 2019-07-17 Zensun (Shanghai) Science & Technology, Co., Ltd. Extended release of neuregulin for treating heart failure
CN104211799B (zh) 2013-05-29 2017-12-26 成都渊源生物科技有限公司 人源egf结构域蛋白及其应用
CN104758922A (zh) 2014-01-03 2015-07-08 上海泽生科技开发有限公司 纽兰格林制剂的配方
US9352923B2 (en) 2014-02-26 2016-05-31 Eastman Kodak Company Air shoe with roller providing lateral constraint
US20170035848A1 (en) 2014-04-15 2017-02-09 Universiteit Antwerpen Treatment of nephropathy
CN105497876B (zh) 2014-09-24 2021-01-15 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟心脏室性心律失常的方法和组合物
CN111407882A (zh) 2014-10-17 2020-07-14 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物
EP3247380A1 (en) 2015-01-20 2017-11-29 Universiteit Antwerpen Neuregulin in the treatment of fibrotic disorders
US10017574B2 (en) 2015-05-07 2018-07-10 Yeda Research And Development Co. Ltd. Methods, kits and devices for promoting cardiac regeneration
EP3355909B1 (en) 2015-09-28 2023-06-07 Children's Hospital Los Angeles Methods for treating diseases mediated by erbb4-positive pro-inflammatory macrophages
EP4361177A3 (en) 2018-04-11 2024-08-14 Salubris Biotherapeutics, Inc. Human neuregulin-1 (nrg-1) recombinant fusion protein compositions and methods of use thereof
AR121035A1 (es) * 2019-04-01 2022-04-13 Lilly Co Eli Compuestos de neuregulina-4 y métodos de uso

Also Published As

Publication number Publication date
TWI787596B (zh) 2022-12-21
PE20212326A1 (es) 2021-12-14
BR112021017670A2 (pt) 2021-11-16
ZA202304093B (en) 2024-09-25
JP2021522314A (ja) 2021-08-30
MA55532A (fr) 2022-02-09
WO2020205840A1 (en) 2020-10-08
SG11202110484VA (en) 2021-10-28
EP3947428A1 (en) 2022-02-09
IL286697A (en) 2021-10-31
US12145972B2 (en) 2024-11-19
CA3132135A1 (en) 2020-10-08
TW202104251A (zh) 2021-02-01
US20200354421A1 (en) 2020-11-12
US20220112255A1 (en) 2022-04-14
CN113677699B (zh) 2024-06-11
AU2020252184B2 (en) 2022-12-08
CL2021002455A1 (es) 2022-05-27
CN113677699A (zh) 2021-11-19
AR121035A1 (es) 2022-04-13
CA3223554A1 (en) 2020-10-08
US20250092107A1 (en) 2025-03-20
CO2021012807A2 (es) 2021-10-29
KR20210134699A (ko) 2021-11-10
JOP20210264A1 (ar) 2023-01-30
EA202192288A1 (ru) 2022-01-21
DOP2021000194A (es) 2021-10-31
KR102717638B1 (ko) 2024-10-16
CR20210474A (es) 2021-10-13
US11242370B2 (en) 2022-02-08
AU2020252184A1 (en) 2021-10-14
ZA202106570B (en) 2025-01-29
MX2021011983A (es) 2021-11-03
JP7036953B2 (ja) 2022-03-15
PH12021552427A1 (en) 2022-07-11

Similar Documents

Publication Publication Date Title
CO2021012807A2 (es) Compuestos de neuregulina-4 y métodos de uso
MX2023007852A (es) Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos.
MX2022007841A (es) Degradadores del regulador dependiente de actina asociado a la matriz relacionado con el complejo switch/sacarosa no fermentable de la subfamilia a de la cromatina (smarca)y usos de los mismos.
MX2020008772A (es) Conjugados de il-15, y sus usos.
CL2019003892A1 (es) Nuevos derivados de azaquinolina.
CL2021003105A1 (es) Inhibidores de masp-2 y métodos de uso (divisional de la solicitud no. 202003083)
MX2020013853A (es) Compuestos innovadores.
MX2020002823A (es) Fluorofenil beta-hidroxietilaminas y su uso en el tratamiento de la hiperglucemia.
BR112021011124A2 (pt) Anelossomos e métodos de uso
CO2022000481A2 (es) Inhibidores de enzimas
CL2021002318A1 (es) Métodos de tratamiento de amiloidosis al
WO2019183215A3 (en) Halloysite-based nanocomposites and methods of making and using the same
MX2021015961A (es) Moleculas novedosas.
MX2020009733A (es) Composiciones.
MX2021010152A (es) Moduladores de la expresion de malat1.
AR106981A1 (es) Una composición antimicrobiana
PH12020550081A1 (en) Transdermal formulations
CO2022000270A2 (es) Inhibidores de enzimas
MX2025005584A (es) Recubrimientos resistentes a la incrustacion biologica y metodos para elaborar y usar los mismos
MX2021005533A (es) Trigliceridos mixtos.
MX420767B (es) Proteina de union al factor h modificada
PH12019501354A1 (en) Personal care compositions with cystine
CL2021002501A1 (es) Compuestos novedosos y métodos de uso de los mismos.
BR112022024988A2 (pt) Compostos e métodos para tratamento de infecções fúngicas
MX2021015879A (es) Peptidos restringidos.